Research News and Research

RSS

CMX157 shows potential to suppress replication of HIV in Phase 1 clinical trial

Chimerix, Inc., a biopharmaceutical company developing orally-available antiviral therapeutics, today announced the publication of research results demonstrating the potential of CMX157 (hexadecyloxypropyl tenofovir) to effectively suppress replication of human immunodeficiency virus (HIV) that cannot be treated with currently available nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), including tenofovir disoproxil fumarate (Viread), due to the development of multi-drug resistance. Earlier this year, Chimerix initiated a dose-escalating Phase 1 clinical trial of CMX-157 to evaluate drug safety, tolerability and pharmacokinetics.

29 Jul 2010

Rite Aid agrees to pay $1 million to settle medical privacy questions

The Wall Street Journal: "Rite Aid Corp. agreed to pay $1 million to settle potential violations of government privacy rules after regulators said it failed to protect customers' and employees' financial and medical information. The drug-store chain's agreement with the Federal Trade Commission requires the company to establish an information-security program and obtain a third-party audit of its compliance to that effect every two years for the next 20 years."

29 Jul 2010

NIH grants $14.85 million to complete two floors of NRI at Texas Children's Hospital

Neurological research at Baylor College of Medicine and Texas Children's Hospital is getting a big boost in the form of a $14.85 million grant from the National Institutes of Health to complete two floors of the Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital.

29 Jul 2010

Hospitals focus on forming ACOs, resolving insurer disputes

News outlets report on hospital issues, including forming accountable care organizations and disputes with insurers.

29 Jul 2010

Increased SIRT1 protein can delay delay aging, extend lifespan

Researchers watched two groups of mice, both nearing the end of a two-day fast. One group was quietly huddled together, but the other group was active and alert. The difference? The second set of mice had been engineered so their brains produced more SIRT1, a protein known to play a role in aging and longevity.

29 Jul 2010

Inhibition of MMPs can offer therapeutic benefit in Huntington's disease: Study

A new study reveals that an enzyme linked with multiple disorders is also involved in the generation of toxic, neuron-killing protein fragments in Huntington's disease (HD). The research, published by Cell Press in the July 29 issue of Neuron, provides insight into Huntington's pathology and proposes new therapeutic strategies for this devastating incurable disease.

29 Jul 2010

Anti-fraud efforts backed by AARP; Seniors cautioned about rebate cons

AARP on Tuesday "threw its influence" behind a number of plans to reduce Medicare fraud, including the bipartisan Medicare Fraud Enforcement and Prevention Act, which would increase penalties on nabbed fraudsters and supply more claims data to enforcers, The Hill reports. Separate legislation, "the Fighting Fraud with Innovative Technology Act, would bolster Medicare's claims screening process before payments are sent out" (Lillis, 7/27).

29 Jul 2010

Aggressive prostate cancer patients tend to retain denser bones

Men who develop prostate cancer, especially the more aggressive and dangerous forms that spread throughout the body, tend to retain denser bones as they age than men who stay free of the disease, suggests new research from Johns Hopkins and the National Institute on Aging (NIA), part of the National Institutes of Health.

29 Jul 2010

AMAG attributes increased second-quarter revenues of $18.8 million to Feraheme

AMAG Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today reported unaudited consolidated financial results for the second quarter and six months ended June 30, 2010. For the second quarter, AMAG reported total revenue of $18.8 million, including $16.0 million of Feraheme® (ferumoxytol) Injection for intravenous (IV) use net product revenues.

29 Jul 2010

States continue push for extension of extra Medicaid funds

News outlets report on state budget gaps and lobbying for extra Medicaid funds from the federal government.

29 Jul 2010

Scientists identify new catalytic process to create pharmaceuticals with less chemical waste

Much like two children in the back seat of a car, it can be challenging to get two catalysts to cooperate for the greater good. Now Northwestern University chemists have gotten two catalysts to work together on the same task -- something easily done by nature but a difficult thing to do in the laboratory.The findings, published by the journal Nature Chemistry, will allow medicinal chemists to invent new reactions and produce valuable bioactive compounds faster with less impact on the environment.

29 Jul 2010

Limerick to announce new results from LIM-0705 human trials at 23rd Transplantation Society congress

Limerick BioPharma, Inc., a developer of innovative therapies that help cells pump out unwanted or toxic substances, will announce new results from human trials of its lead compound, LIM-0705, at the 23rd International Congress of the Transplantation Society in Vancouver, Canada, in an oral presentation on August 19, 2010.

29 Jul 2010

Pretreating polycarbonate plastic is an eco-friendly way of waste disposal: Research

Just as cooking helps people digest food, pretreating polycarbonate plastic - source of a huge environmental headache because of its bisphenol A (BPA) content - may be the key to disposing of the waste in an eco-friendly way, scientists have found. Their new study is in ACS' Biomacromolecules, a monthly journal.

29 Jul 2010

HIV drug can raise the risk of heart disease: Study

There are a handful of drugs effective in treating HIV/AIDS. However new research shows that some of these drugs can increase the risk of heart attacks. The results come from a Garvan Institute of Medical Research study involving 20 people, 10 taking the drug Ritonavir and 10 others the drug Raltegravir for one month.

28 Jul 2010

Mobile phones dirtier than we thought: Study

According to research for a UK consumer group mobile phones can harbor 18 times more living bacteria than a lavatory seat. For the study a hygiene expert swabbed and analysed 30 handsets and found seven had high levels of environmental bacteria.

28 Jul 2010

Intercept signs CRADA with NIDDK for study of obeticholic acid in nonalcoholic steatohepatitis

Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing novel therapeutics for chronic fibrotic and metabolic diseases, today announced the signing of a cooperative research and development agreement (CRADA) with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health to conduct a double blind, multi-center, study to evaluate the effects of obeticholic acid in patients with nonalcoholic steatohepatitis (NASH).

28 Jul 2010

Pain Therapeutics second-quarter collaboration revenue decreases to $0.1 million

Pain Therapeutics, Inc., a biopharmaceutical company, today reported second quarter financial results. Net loss for the quarter ended June 30, 2010 was $0.8 million, or $0.02 per share, compared to net loss of $34,000, or $0.00 per share, for the second quarter of 2009. Pain Therapeutics had cash, cash equivalents and marketable securities of $176.2 million, or about $4.14 cash per share, and no debt as of June 30, 2010.

28 Jul 2010

Hospira second-quarter 2010 net sales increase 1.2% to $968 million

Hospira, Inc., a leading global specialty pharmaceutical and medication delivery company, today reported results for the second quarter ended June 30, 2010. Net sales for the quarter were $968 million, and adjusted diluted earnings per share were $0.86.

28 Jul 2010

Bruker second-quarter adjusted EPS grows 114% y-o-y to $0.15

Bruker Corporation today reported financial results for the three and six months ended June 30, 2010.

28 Jul 2010

Clinical Pharmacokinetics Research Laboratory deploys AB SCIEX mass spectrometry technology

AB SCIEX, a global leader in life science analytical technologies, today announced that the Clinical Pharmacokinetics Research Laboratory at the University of Rhode Island's College of Pharmacy is using AB SCIEX mass spectrometry technology to develop a novel test that would enable clinical researchers to use saliva to monitor immunosuppressant drugs commonly administered to make organ transplants successful.

28 Jul 2010

Research News and Research

CMX157 shows potential to suppress replication of HIV in Phase 1 clinical trial

Rite Aid agrees to pay $1 million to settle medical privacy questions

NIH grants $14.85 million to complete two floors of NRI at Texas Children's Hospital

Hospitals focus on forming ACOs, resolving insurer disputes

Increased SIRT1 protein can delay delay aging, extend lifespan

Inhibition of MMPs can offer therapeutic benefit in Huntington's disease: Study

Anti-fraud efforts backed by AARP; Seniors cautioned about rebate cons

Aggressive prostate cancer patients tend to retain denser bones

AMAG attributes increased second-quarter revenues of $18.8 million to Feraheme

States continue push for extension of extra Medicaid funds

Scientists identify new catalytic process to create pharmaceuticals with less chemical waste

Limerick to announce new results from LIM-0705 human trials at 23rd Transplantation Society congress

Pretreating polycarbonate plastic is an eco-friendly way of waste disposal: Research

HIV drug can raise the risk of heart disease: Study

Mobile phones dirtier than we thought: Study

Intercept signs CRADA with NIDDK for study of obeticholic acid in nonalcoholic steatohepatitis

Pain Therapeutics second-quarter collaboration revenue decreases to $0.1 million

Hospira second-quarter 2010 net sales increase 1.2% to $968 million

Bruker second-quarter adjusted EPS grows 114% y-o-y to $0.15

Clinical Pharmacokinetics Research Laboratory deploys AB SCIEX mass spectrometry technology

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence